Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.

ABSTRACT: Traditional prognostic models for newly diagnosed patients with multiple myeloma (MM), including International Staging System criteria and number of high-risk chromosomal abnormalities, are based on disease characteristics at diagnosis. However, the identification of patients at risk of more rapidly progressive MM is inherently a dynamic assessment. In a subset of patients with MM, adverse disease biology only becomes evident after the failure of first-line therapy. We define this entity as functional high-risk MM (FHRMM), encompassing relapse within 18 months of treatment initiation and/or within 12 months of frontline autologous stem cell transplantation. FHRMM is not adequately captured by traditional prognostic models, and there is a need for better understanding of mechanisms or risk

SUBMITTER: Banerjee R 

PROVIDER: S-EPMC10577204 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature